Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Expediting International Clinical Trials for Pivotal Products
Key Participants Include International Long-Term and Healthcare Funds
HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately $250 million USD through a share placement. This offering has earned notable recognition among international investment firms, with the majority of our final subscribers being long-term funds and healthcare funds.
This marks Akeso's second successful share placement in 2024. Following this transaction, the Company's cash on hand are expected to be 1.064 billion USD (7.5 billion RMB).
Seventy percent of the financing will be allocated to accelerating the global clinical development of innovative drugs developed internally by Akeso, with a primary focus on its core products in both China and international markets.
Dr. Xia Yu, Founder, Chairwoman, President, and Chief Executive Officer of Akeso Biopharma, stated: "The efficient completion of this share placement reflects Akeso's long-term investment value being highly recognized by international long-term institutional investors and specialized institutions in the healthcare sector. The success of this financing will bolster Akeso's global development strategy for a diversified pipeline of independently developed new drugs, particularly by accelerating multi-center international clinical trials led by Akeso. This initiative will enhance the global value exploration of our internally developed new drugs and further strengthen our competitiveness in the international market."
The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.
Antibody drug conjugates (ADCs) have emerged as a transformative class of...
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in four prominent healthcare investor conferences over the coming weeks, providing...
Vance Street Capital ("Vance Street"), a Los Angeles-based private equity firm, announced it has partnered with the Prince Sterilization Services ("Prince" or the "Company") management team to support the Company's continued growth. The strategic...
Today Bruin Biometrics and Arjo announce the immediate transition of direct sales and marketing of the Provizio® SEM Scanner to Bruin Biometrics, following four years of cooperation between the companies.
As communicated earlier this year, the...
The "CRISPR Technology Market" report has been added to ResearchAndMarkets.com's offering.
The CRISPR Technology Market was valued at USD 2024 in 2029, and is expected to reach USD 3.8 billion by 7.5 billion, rising at a CAGR of 14.4%.
This report...
The American Chemistry Council (ACC) issued the following statement that may be attributed to ACC President and CEO, Chris Jahn, in response to the 2024 Presidential and Congressional election results:
"ACC and our member companies congratulate...